Automated oxygen titration with non-invasive ventilation in hypoxaemic adults with cardiorespiratory disease: a randomised cross-over trial.
Autor: | Kirton L; Medical Research Institute of New Zealand, Wellington, New Zealand louis.kirton@mrinz.ac.nz.; Victoria University Wellington, Wellington, New Zealand., Kung S; Medical Research Institute of New Zealand, Wellington, New Zealand., Bird G; Medical Research Institute of New Zealand, Wellington, New Zealand., Black M; Medical Research Institute of New Zealand, Wellington, New Zealand., Semprini R; Medical Research Institute of New Zealand, Wellington, New Zealand., Eathorne A; Medical Research Institute of New Zealand, Wellington, New Zealand., Weatherall M; University of Otago Wellington, Wellington, New Zealand., Semprini A; Medical Research Institute of New Zealand, Wellington, New Zealand.; Victoria University Wellington, Wellington, New Zealand., Beasley R; Medical Research Institute of New Zealand, Wellington, New Zealand.; Victoria University Wellington, Wellington, New Zealand. |
---|---|
Jazyk: | angličtina |
Zdroj: | BMJ open respiratory research [BMJ Open Respir Res] 2024 Jun 18; Vol. 11 (1). Date of Electronic Publication: 2024 Jun 18. |
DOI: | 10.1136/bmjresp-2023-002196 |
Abstrakt: | Background: Closed-loop oxygen control systems automatically adjust the fraction of inspired oxygen (FiO Methods: In this open-label, three-way cross-over trial, participants with resting hypoxaemia (n=12) received each of NHF, bilevel and CPAP treatments, in random order, with automated oxygen titrated for 10 min, followed by 36 min of standardised manual oxygen adjustments. The primary outcome was the time taken to reach target SpO Results: Two participants were randomised to each of six possible treatment orders. During automated oxygen control (n=12), the mean (±SD) time to reach target range was 114.8 (±87.9), 56.6 (±47.7) and 67.3 (±61) seconds for NHF, bilevel and CPAP, respectively, mean difference 58.3 (95% CI 25.0 to 91.5; p=0.002) and 47.5 (95% CI 14.3 to 80.7; p=0.007) seconds for bilevel and CPAP versus NHF, respectively. Proportions of time spent within target range were 68.5% (±16.3), 65.6% (±28.7) and 74.7% (±22.6) for NHF, bilevel and CPAP, respectively.Manually increasing, then decreasing, the FiO Conclusion: The target SpO Trial Registration Number: ACTRN12622000433707. Competing Interests: Competing interests: LK, SK, GB, MB, RS, AS, AE and RB report financial support was provided by Fisher & Paykel Healthcare to conduct this study. RB reports that the Institute responsible for this study manuscript has received research funding from Fisher and Paykel Healthcare and the Health Research Council of New Zealand. LK reports a relationship with Fisher & Paykel Healthcare that includes: travel reimbursement. Coauthor RS reports a relationship with Fisher & Paykel Healthcare that includes conference fees. Coauthor GB is now employed by Johnson & Johnson Pacific. Coauthor AS was on a Data Safety Management Committee for a separate study funded by Fisher & Paykel Healthcare. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.) |
Databáze: | MEDLINE |
Externí odkaz: |